Ceftazidime Can Potentially Inhibit SARS-CoV-2

Repurposing drugs used in other diseases may work for SARS-CoV-2. These drugs are already approved for humans and can be immediately used in humans. Researchers at the Chinese Academy of Sciences screened 3581 molecules and found 75 compounds showing 45% inhibition.

Further refining revealed that ceftazidime had a relative inhibition rate of about 81%. Ceftazidime is approved for treating bacterial pneumonia. Further research revealed that ceftazidime binds specifically to the spike protein receptor-binding domain (RBD) of the coronavirus.

This prevented the binding of the coronavirus to the human pulmonary alveolar epithelial lung cell. It also prevented the entry of the SARS-CoV-2 pseudovirus. The IC50 of ceftazidime was about 113µM and did not show any measurable toxicity up to 400µM.

This action of ceftazidime might be due to the chemical functionalities 2-aminothiazole, oxime with a terminal-exposed isobutyric acid, and positively charged pyridine. The strong binding of ceftazidime to the spike protein RBD suggests covalent bonding.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.biorxiv.org/content/10.1101/2020.09.14.295956v1